相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones
Roos Houtsma et al.
BLOOD ADVANCES (2022)
Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch
Walid Warda et al.
CANCER GENE THERAPY (2021)
Therapeutic Strategies for Targeting IL-1 in Cancer
Adrian Gottschlich et al.
CANCERS (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Mehmet Kemal Samur et al.
NATURE COMMUNICATIONS (2021)
Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
Laura Jimbu et al.
PHARMACEUTICALS (2021)
Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients
Rafik Haderbache et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma
Hai-Feng Zhang et al.
CANCER DISCOVERY (2021)
The IL1-IL1RAP axis plays an important role in the inflammatory leukemic niche that favors acute myeloid leukemia proliferation over normal hematopoiesis
Bauke De Boer et al.
HAEMATOLOGICA (2021)
The Potential Role of IL1RAP on Tumor Microenvironment-Related Inflammatory Factors in Stomach Adenocarcinoma
Qing Lv et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2021)
State of the art in CAR T cell therapy for CD19+ B cell malignancies
Matthew J. Frigault et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana et al.
FRONTIERS IN ONCOLOGY (2020)
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
Yuru Nie et al.
BIOMARKER RESEARCH (2020)
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
Melat T. Gebru et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics
Xavier Roussel et al.
FRONTIERS IN ONCOLOGY (2020)
Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia
Frederick Fasslrinner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies.
Ahmad Awada et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Susanne Hofmann et al.
JOURNAL OF CLINICAL MEDICINE (2019)
CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells
Walid Warda et al.
CANCER RESEARCH (2019)
The emerging role of immune checkpoint based approaches in AML and MDS
Prajwal Boddu et al.
LEUKEMIA & LYMPHOMA (2018)
Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies
Michael D. Jain et al.
STEM CELLS (2018)
IL1RAP potentiates multiple oncogenic signaling pathways in AML
Kelly Mitchell et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer
Pengfei Zheng et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice
Adi Litmanovich et al.
ONCOLOGY AND THERAPY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
The role of targeted therapy in the management of patients with AML
Alexander E. Perl
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Prithviraj Bose et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
Helena Agerstam et al.
BLOOD (2016)
LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis
Adam Ceroi et al.
BLOOD (2016)
Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution
M. Ryan Corces et al.
NATURE GENETICS (2016)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Saar Gill et al.
BLOOD (2014)
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
Denise Wolleschak et al.
HAEMATOLOGICA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Blood soluble interleukin 1 receptor accessory protein levels are consistently low throughout the menstrual cycle of women with endometriosis
Nadege Michaud et al.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Maria Askmyr et al.
BLOOD (2013)
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
Laura Barreyro et al.
BLOOD (2012)
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells
R. Majeti
ONCOGENE (2011)
分享论文
